Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (KRON) is a clinical-stage biopharmaceutical company pioneering small molecule therapeutics that target deregulated transcription in cancer and autoimmune disorders. This page provides investors and industry observers with essential updates on the company’s progress, including clinical trial milestones, financial disclosures, and strategic partnerships.
Access real-time announcements about KRON’s innovative pipeline candidates, including CDK9 and p300 KAT inhibitors designed to address high-need oncology indications. Our curated news collection offers insights into the company’s proprietary discovery engine and precision medicine approach while maintaining compliance with financial reporting standards.
Key updates cover earnings reports, research collaborations, regulatory developments, and scientific presentations. Bookmark this page for streamlined access to KRON’s latest advancements in transcription factor therapeutics and biopharmaceutical innovation.
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6-8, 2023, in Boston, Massachusetts. CEO Norbert Bischofberger will speak on the ‘Novel Oncology Targets’ panel on March 7 at 9:10 a.m. ET. The discussion will be available via webcast on the company’s website, with a replay accessible for 30 days post-event.
Kronos Bio focuses on developing cancer treatments, including the CDK9 inhibitor KB-0742 for MYC-amplified solid tumors and lanraplenib for FLT3-mutated acute myeloid leukemia.
Kronos Bio has announced a $20 million upfront payment following a collaboration with Genentech aimed at discovering small-molecule drugs for oncology. This deal could yield up to $554 million in milestone payments based on various clinical and commercial achievements. The partnership will focus on enhancing understanding of oncogenic transcription factors using Kronos Bio's proprietary drug discovery platform. Kronos Bio will manage initial preclinical activities before Genentech takes over for further development.
Kronos Bio is presenting promising preclinical data on lanraplenib, a next-generation SYK inhibitor, showcased at the 64th ASH Annual Meeting. The data suggests that lanraplenib has significant anti-leukemic activity, particularly when combined with gilteritinib, in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). The company plans to release initial trial data and recommended Phase 2 dose in late 2023 or early 2024. Additionally, the company emphasized its leadership in advancing measurable residual disease (MRD) as a factor in AML treatment and outcomes.
Kronos Bio, Inc. (Nasdaq: KRON) has announced its advancement to the Phase 2 stage of its clinical trial for KB-0742, a CDK9 inhibitor aimed at treating MYC-amplified tumors. The trial's Phase 1 results indicate a recommended Phase 2 dose (RP2D) of 60 mg, achieving a targeted reduction of 50% in phosphorylated Ser2 on RNA Polymerase II. The compound demonstrated a favorable pharmacokinetic profile with a long half-life of 24 hours. The company will present detailed trial results at a medical conference in late 2023.
Kronos Bio, Inc. (Nasdaq: KRON), focused on cancer treatments, announced its management team's participation in two upcoming investor conferences. The events include the Piper Sandler's 34th Annual Healthcare Conference on November 29, 2022, at 11:30 a.m. ET, and Evercore ISI's 5th Annual HealthCONx on December 1, 2022, at 1 p.m. ET. Investors can access the fireside chats live and view replays on the company's website. Kronos Bio is advancing two investigational compounds: a CDK9 inhibitor for MYC-amplified solid tumors and lanraplenib for FLT3-mutated acute myeloid leukemia.
Kronos Bio, Inc. (Nasdaq: KRON) announced the prioritization of its clinical portfolio, focusing on the next-generation SYK inhibitor, lanraplenib, and the CDK9 inhibitor, KB-0742. The company will discontinue the Phase 3 entospletinib trial due to projected enrollment delays, not due to adverse events. Financially, as of September 30, 2022, Kronos reported $270.3 million in cash and investments, enough to fund operations into Q2 2025. In Q3 2022, it recorded a net loss of $32.3 million or $0.57 per share, while R&D expenses totaled $23.4 million.
Kronos Bio has announced the discontinuation of the Phase 3 clinical trial for its SYK inhibitor, entospletinib, due to strategic reasons including enrollment challenges and the impact of COVID-19. The company will focus on its next-generation SYK inhibitor, lanraplenib, currently in a Phase 1/2b trial for relapsed/refractory AML, and its CDK9 inhibitor, KB-0742, which is also in Phase 1/2 trials. With $270.3 million in cash, Kronos Bio extends its cash runway into Q2 2025, anticipating updates on clinical progress in Q4 2023.
Kronos Bio, Inc. (Nasdaq: KRON) announced plans to present preclinical data on KB-0742, an oral CDK9 inhibitor, at the EORTC-NCI-AACR Symposium from Oct. 26-28, 2022, in Barcelona.
The data showed that KB-0742 induced regressions in neuroblastoma tumors and inhibited growth in models of Ewing sarcoma and rhabdomyosarcoma. This marks the first preclinical support for KB-0742's potential in pediatric tumors. The company aims to update on the recommended Phase 2 dose for KB-0742 in Q4 2022.
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, with an on-demand webcast set for September 12, 2022, at 7 a.m. ET. This webcast will be accessible via the Kronos Bio website, where a replay will be available for 30 days. The company is focused on advancing three investigational compounds for cancer treatment, including entospletinib, a SYK inhibitor, currently in a Phase 3 trial for newly diagnosed NPM1-mutated acute myeloid leukemia. Kronos Bio operates from San Mateo, Calif., and has a research facility in Cambridge, Mass.
Kronos Bio, Inc. (Nasdaq: KRON) announced the initiation of a Phase 1b/2 clinical trial for lanraplenib, a next-generation SYK inhibitor, in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). The trial will assess safety, pharmacokinetics, and anti-leukemic activity in combination with gilteritinib. This study is crucial as it aims to establish lanraplenib as a key treatment option for a significant patient population. Additionally, the company is advancing other investigational compounds, including entospletinib in a Phase 3 trial for NPM1-mutated AML and KB-0742 for MYC-amplified solid tumors.
